PL3319963T3 - Podstawione 4-azaindole i ich zastosowanie jako modulatorów receptora GluN2B - Google Patents
Podstawione 4-azaindole i ich zastosowanie jako modulatorów receptora GluN2BInfo
- Publication number
- PL3319963T3 PL3319963T3 PL16741469T PL16741469T PL3319963T3 PL 3319963 T3 PL3319963 T3 PL 3319963T3 PL 16741469 T PL16741469 T PL 16741469T PL 16741469 T PL16741469 T PL 16741469T PL 3319963 T3 PL3319963 T3 PL 3319963T3
- Authority
- PL
- Poland
- Prior art keywords
- azaindoles
- substituted
- receptor modulators
- glun2b receptor
- glun2b
- Prior art date
Links
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical class C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 title 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562190416P | 2015-07-09 | 2015-07-09 | |
| EP16741469.7A EP3319963B1 (en) | 2015-07-09 | 2016-07-07 | Substituted 4-azaindoles and their use as glun2b receptor modulators |
| PCT/US2016/041339 WO2017007938A1 (en) | 2015-07-09 | 2016-07-07 | Substituted 4-azaindoles and their use as glun2b receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3319963T3 true PL3319963T3 (pl) | 2020-06-01 |
Family
ID=56497884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16741469T PL3319963T3 (pl) | 2015-07-09 | 2016-07-07 | Podstawione 4-azaindole i ich zastosowanie jako modulatorów receptora GluN2B |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9963447B2 (pl) |
| EP (1) | EP3319963B1 (pl) |
| JP (2) | JP6964576B2 (pl) |
| KR (1) | KR20180026760A (pl) |
| CN (1) | CN108026094B (pl) |
| AU (1) | AU2016291158B2 (pl) |
| BR (1) | BR112018000468A2 (pl) |
| CA (1) | CA2991765C (pl) |
| CY (1) | CY1123007T1 (pl) |
| DK (1) | DK3319963T3 (pl) |
| EA (1) | EA033197B1 (pl) |
| ES (1) | ES2781867T3 (pl) |
| HR (1) | HRP20200410T1 (pl) |
| HU (1) | HUE047460T2 (pl) |
| IL (1) | IL256758A (pl) |
| LT (1) | LT3319963T (pl) |
| MA (1) | MA42397B1 (pl) |
| MD (1) | MD3319963T2 (pl) |
| MX (1) | MX2018000352A (pl) |
| PL (1) | PL3319963T3 (pl) |
| PT (1) | PT3319963T (pl) |
| SI (1) | SI3319963T1 (pl) |
| SM (1) | SMT202000134T1 (pl) |
| WO (1) | WO2017007938A1 (pl) |
| ZA (1) | ZA201800827B (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE049278T2 (hu) | 2014-08-15 | 2020-09-28 | Janssen Pharmaceuticals Inc | Pirazolok |
| JP6605020B2 (ja) | 2014-08-15 | 2019-11-13 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Ｎｒ２ｂ受容体阻害剤としてのトリアゾール |
| SMT202000134T1 (it) | 2015-07-09 | 2020-05-08 | Janssen Pharmaceutica Nv | 4-azaindoli sostituiti e loro uso come modulatori del recettore glun2b |
| BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| JP7346441B2 (ja) * | 2018-04-04 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピリジン及びピリミジン並びにｇｌｕｎ２ｂ受容体調節物質としてのそれらの使用 |
| KR20220024403A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| JP7667097B2 (ja) * | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| BR112021025141A2 (pt) * | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b |
| US11618750B2 (en) * | 2019-06-14 | 2023-04-04 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators |
| CA3142998A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as glun2b receptor modulators |
| CA3143102A1 (en) * | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| CN114621125B (zh) * | 2020-12-14 | 2024-07-09 | 中国科学技术大学 | Nlrp3炎症小体抑制剂及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040111445A (ko) * | 2002-03-28 | 2004-12-31 | 에자이 가부시키가이샤 | 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌 |
| BRPI0507501A (pt) | 2004-02-18 | 2007-06-26 | Astrazeneca Ab | composto, composição farmacêutica, uso do composto, método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5 |
| US20060183758A1 (en) * | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
| WO2007115231A2 (en) * | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| AU2008257559B2 (en) | 2007-05-25 | 2013-10-10 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (MGLU2 receptor) |
| WO2009005821A1 (en) | 2007-07-03 | 2009-01-08 | Edward Scott Carlson | Support apparatus for climbing plants |
| BRPI0816095A2 (pt) | 2007-08-30 | 2015-03-03 | Takeda Pharmaceutical | Composto ou um sal do mesmo, pró-droga, agente farmacêutico, métodos para antagonizar um receptor de androgênio e para prevenir / tratar cãncer, e, uso do composto ou uma pró-droga do mesmo. |
| EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
| BRPI0909378A2 (pt) | 2008-03-27 | 2015-10-06 | Evotec Neurosciences Gmbh | métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b |
| PL2308877T3 (pl) | 2008-08-05 | 2014-07-31 | Daiichi Sankyo Co Ltd | Pochodne imidazopirydyn-2-onu |
| US8697689B2 (en) * | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| JP5930278B2 (ja) | 2008-11-25 | 2016-06-08 | ユニバーシティー オブ ロチェスター | Ｍｌｋ阻害剤および使用方法 |
| TWI625121B (zh) * | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| WO2011156245A2 (en) | 2010-06-09 | 2011-12-15 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| WO2014124651A1 (en) * | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| JP2016516710A (ja) * | 2013-03-13 | 2016-06-09 | アッヴィ・インコーポレイテッド | ピリジン系ｃｄｋ９キナーゼ阻害薬 |
| KR102244719B1 (ko) * | 2013-03-15 | 2021-04-26 | 플렉시콘 인코퍼레이티드 | 헤테로시클릭 화합물 및 그의 용도 |
| CN103626767A (zh) * | 2013-12-04 | 2014-03-12 | 上海药明康德新药开发有限公司 | 区域选择性的氮杂吲哚及其合成方法 |
| HUE049278T2 (hu) | 2014-08-15 | 2020-09-28 | Janssen Pharmaceuticals Inc | Pirazolok |
| JP6605020B2 (ja) | 2014-08-15 | 2019-11-13 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Ｎｒ２ｂ受容体阻害剤としてのトリアゾール |
| SMT202000134T1 (it) | 2015-07-09 | 2020-05-08 | Janssen Pharmaceutica Nv | 4-azaindoli sostituiti e loro uso come modulatori del recettore glun2b |
| BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
-
2016
- 2016-07-07 SM SM20200134T patent/SMT202000134T1/it unknown
- 2016-07-07 KR KR1020187003560A patent/KR20180026760A/ko not_active Withdrawn
- 2016-07-07 PL PL16741469T patent/PL3319963T3/pl unknown
- 2016-07-07 MX MX2018000352A patent/MX2018000352A/es unknown
- 2016-07-07 AU AU2016291158A patent/AU2016291158B2/en active Active
- 2016-07-07 SI SI201630594T patent/SI3319963T1/sl unknown
- 2016-07-07 EA EA201890245A patent/EA033197B1/ru not_active IP Right Cessation
- 2016-07-07 JP JP2018500737A patent/JP6964576B2/ja active Active
- 2016-07-07 WO PCT/US2016/041339 patent/WO2017007938A1/en not_active Ceased
- 2016-07-07 MA MA42397A patent/MA42397B1/fr unknown
- 2016-07-07 PT PT167414697T patent/PT3319963T/pt unknown
- 2016-07-07 HR HRP20200410TT patent/HRP20200410T1/hr unknown
- 2016-07-07 DK DK16741469.7T patent/DK3319963T3/da active
- 2016-07-07 CN CN201680052507.9A patent/CN108026094B/zh active Active
- 2016-07-07 MD MDE20180505T patent/MD3319963T2/ro not_active IP Right Cessation
- 2016-07-07 EP EP16741469.7A patent/EP3319963B1/en active Active
- 2016-07-07 LT LTEP16741469.7T patent/LT3319963T/lt unknown
- 2016-07-07 HU HUE16741469A patent/HUE047460T2/hu unknown
- 2016-07-07 ES ES16741469T patent/ES2781867T3/es active Active
- 2016-07-07 BR BR112018000468-5A patent/BR112018000468A2/pt not_active Application Discontinuation
- 2016-07-07 CA CA2991765A patent/CA2991765C/en active Active
- 2016-07-08 US US15/205,632 patent/US9963447B2/en active Active
-
2018
- 2018-01-07 IL IL256758A patent/IL256758A/en unknown
- 2018-02-08 ZA ZA2018/00827A patent/ZA201800827B/en unknown
- 2018-03-20 US US15/926,440 patent/US10377753B2/en active Active
-
2020
- 2020-03-24 CY CY20201100280T patent/CY1123007T1/el unknown
-
2021
- 2021-08-27 JP JP2021138906A patent/JP7369743B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201800827B (en) | Substituted 4-azaindoles and their use as glun2b receptor modulators | |
| IL274537A (en) | nuclear receptor modulators | |
| IL247847B (en) | ror gamma modulator and their use | |
| GB201514875D0 (en) | Receptor | |
| ZA201802901B (en) | Farnesoid x receptor modulators | |
| GB201518816D0 (en) | Receptor | |
| ZA201708065B (en) | Azabenzimidazoles and their use as ampa receptor modulators | |
| GB201411197D0 (en) | Composition and use thereof | |
| IL249896B (en) | New modulators for the glp-1 receptor and their use as drugs | |
| PL3303291T3 (pl) | Modulatory ROR-gamma | |
| PL3303293T3 (pl) | Modulatory ROR-gamma | |
| PL3303290T3 (pl) | Modulatory ROR-gamma | |
| IL254921B (en) | Pyridopyrimidinones and their uses as nmda receptor modulators | |
| PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORγ) | |
| IL266261A (en) | ror-gamma modulators | |
| IL249203B (en) | Androgen receptor modulators and methods of using them | |
| IL252565B (en) | New receptor modulators | |
| GB201411196D0 (en) | Composition and use thereof | |
| ZA201606656B (en) | Ror-gamma modulators and uses thereof | |
| GB201513318D0 (en) | Novel compounds and their use | |
| GB201514770D0 (en) | Compounds and their use | |
| GB201400215D0 (en) | Modulators | |
| GB201500278D0 (en) | Novel combination and use | |
| GB201413411D0 (en) | Novel compounds and their use | |
| GB201407736D0 (en) | Hammock blanket |